[Skip to Content]
[Skip to Content Landing]
Views 4,124
Citations 0
February 24, 2015

Potential Hazards of Adding Nonsteroidal Anti-inflammatory Drugs to Antithrombotic Therapy After Myocardial InfarctionTime for More Than a Gut Check

Author Affiliations
  • 1Division of Cardiovascular Medicine, University of Tennessee–Chattanooga
  • 2Gill Heart Institute and Division of Cardiovascular Medicine, University of Kentucky, Lexington
JAMA. 2015;313(8):801-802. doi:10.1001/jama.2015.0567

Nonsteroidal anti-inflammatory drugs (NSAIDs) block prostaglandin and prostacyclin biosynthesis via their inhibition of cyclooxygenase (COX) enzymes. By inhibiting COX-1, aspirin reduces thromboxane production, and this leads to its antiplatelet effect. By more effectively inhibiting COX-2, other NSAIDs have relatively greater anti-inflammatory, antipyretic, and analgesic effects. The adverse effect profile of nonselective NSAIDs includes bleeding, particularly gastrointestinal bleeding, which is thought to result from gastric irritation, antiplatelet effects, and the loss of prostaglandin-mediated mucosal repair.1 Selective inhibitors of COX-2 were developed with the hope they would have fewer gastrointestinal adverse effects and would be highly effective against chronic inflammatory states, such as arthritis.

First Page Preview View Large
First page PDF preview
First page PDF preview